Table 2.
Peer-reviewed studies showing the effectiveness of CytoSorb® treatment.
| S. No. | No. of Patients | Study Type | Comorbidities/Indication of CytoSorb® | Clinical Outcomes |
|---|---|---|---|---|
| 1. | 198 | Retrospective control study | Septic shock | Early start of CytoSorb® therapy significantly improved the survival of septic shock patients. A dynamic scoring system to assess the efficacy of CytoSorb® therapy was also developed. |
| 2. | 116 | Retrospective study | Septic shock | Improvement in 28-day survival, both on the basis of observed versus predicted mortality rates, was observed in CytoSorb® + CRRT group as compared CRRT alone group. |
| 3. | 100 | Observational and retrospective study | Sepsis and septic shock. | Survivors (n = 40) Non-survivors (n = 60) |
| 4. | 84 (Group 1: CytoSorb + CRRT, 42; Group 2: CRRT) | Retrospective genetic matched control study | Septic Shock | Catecholamines levels were reduced to half within 24 h after initiation of CytoSorb therapy. In hospital and 28-day mortality were reduced in CytoSorb® group |
| 5. | 45 | Observational multicenter study | Sepsis and septic shock. | Mortality rate: 48.8% after CytoSorb® therapy. 75% survival rate in patients given treatment in <24 h of ICU admission and 68% survival rates within 24–48 h of ICU admission |
| 6. | 36 | Observational and retrospective study | Sepsis and septic shock | Procalcitonin and total leucocyte count was reduced within 24 h of initiation of therapy. Sepsis related SOFA score was reduced. Survivors (17) Non-survivors (n = 19) |
| 7. | 26 | Retrospective case series | COVID-19 and acute respiratory distress syndrome | Significant reductions in norepinephrine, and inflammatory markers, with improvements in respiratory and other organ functions by use of CytoSorb®. |
| 8. | 25 (Group 1: CRRT, 15; Group 2: CRRT + CytoSorb®) | Retrospective analysis | Multiorgan dysfunction syndrome | Mortality rate: 53.3% in Group I and 60.0% in Group II |
| 9. | 16 (CytoSorb®: 8; control: 8) | Retrospective pilot study | Elective major aortic surgery for aortic aneurysm and/or aortic dissection. | |
| 10. | 13 | Retrospective case series | COVID-19, organ failure and acute respiratory distress syndrome | Significant reduction in inflammatory mediators (interleukin 6), hemodynamic stabilization with a concomitant decrease in requirements for vasoactive substances (norepinpethrine), and a pronounced improvement in lung function were observed with combined therapy of CRRT and CytoSorb® |
| 11. | 3 1 |
Case Series Case Study |
Hypertension Respiratory failure type-1/Other Hypertension Diabetes/Septic with shock Septic shock with multi-organ dysfunction (MODS) and a low perfusion state with a history of diabetes mellitus type II, hypertension, obstructive sleep apnea, hypothyroidism and morbid obesity. |
Significant improvement in biochemical parameters and mean arterial pressure was observed with reduction in C-reactive proteins. All patients survived |
| 12. | 1 | Case Study | Septic shock with multi-organ dysfunction (MODS) and a low perfusion state with a history of diabetes mellitus type II, hypertension, obstructive sleep apnea, hypothyroidism and morbid obesity. | Reduction in lactate levels with improved clinical parameters were observed post-CytoSorb® therapy. Vasopressor requirement was reduced to nil. Patient survived |
| 13. | 1 | Case Study | Dengue haemorrhagic fever associated with SIRS, acute fulminant hepatic failure with encephalopathy and oliguria | Liver function tests i.e., SGOT, SGPT were improved with improved platelet count. Patient was hemodynamically stable during discharge. |
| 14. | 1 | Case Study | Dengue fever with septic shock and multiorgan failure admitted in the intensive care. | Survived |
| 15. | 1 | Case Study | SIRS and renal dysfunction after heart transplantation | Vasopressor was weaned completely post-CytoSorb therapy with reduction in serum lactate levels depicting clinical improvement in patient. |
| 16. | 1 | Case Study | Acute Kidney Injury due to Rhabdomyolysis | Patient showed hemodynamic stability post-CytoSorb® therapy and survived |
| 17. | 1 | Case Study | Sepsis complicated by typhoid fever | Survived |
| 18. | 1 | Case Report | Sepsis with multiple organ dysfunction syndrome with the manifestation of acute respiratory distress syndrome (ARDS) and acute renal failure (AKI) | Reduction in catecholamine demand with reduction in serum lactate levels. Patient survived |
| 19. | 1 | Case report | Sepsis with multiple organ dysfunction syndrome | Survived |